Immunotherapy plus chemotherapy

BIOLOGICAL2 trials

Sponsors

Aduro Biotech, Inc., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Malignant Pleural MesotheliomaMuscle-invasive Bladder Cancer

Phase 1

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

CompletedNCT01675765

Aduro Biotech, Inc.Malignant Pleural Mesothelioma

Start: 2014-09-03End: 2019-08-19Updated: 2020-09-30

Unknown Phase

Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

Not yet recruitingNCT07440901

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMuscle-invasive Bladder Cancer

Start: 2026-02-01End: 2027-05-01Target: 30Updated: 2026-02-27

Related Papers

A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2019-03-1015 citations

CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2016-05-204 citations

Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2015-05-208 citations

Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2014-05-207 citations